Breaking News

Eisai Licenses Tasurgratinib to SciClone in Greater China Region

Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Eisai Co., Ltd. has entered into a license agreement granting the exclusive development and distribution rights for the fibroblast growth factor (FGF) receptor selective tyrosine kinase inhibitor tasurgratinib succinate TASFYGO, (tasurgratinib) to a subsidiary of SciClone Pharmaceuticals, in the Greater China region. Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions and continue to manufacture and market it in Japan, where it has been already launched. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters